Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.85 |
| ▸ | LIFR | P42702 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180584 | 0.92 | NR1H4 (0.87) | NR1H4LIFRCYP1A2CYP2C9 | |
| SCHEMBL21624442 | 0.92 | NR1H4 (1.00) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL1179357 | 0.91 | NR1H4 (0.88) | NR1H4LIFRCYP1A2CYP2C9 | |
| SCHEMBL2114048 | 0.91 | NR1H4 (1.00) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL2114897 | 0.90 | NR1H4 (1.00) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL2000350 | 0.90 | NR1H4 (0.85) | NR1H4LIFRCYP1A2CYP2C9 | |
| SCHEMBL28530824 | 0.89 | NR1H4 (1.00) | NR1H4LIFR | |
| SCHEMBL12571945 | 0.88 | NR1H4 (0.84) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL2005313 | 0.87 | NR1H4 (0.85) | NR1H4CYP1A2CYP2C9 | |
| SCHEMBL4950471 | 0.87 | NR1H4 (0.66) | NR1H4LIFRCYP1A2CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158665-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1962838-B1 | FARNESOID X RECEPTOR AGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | GLAXOSMITHKLINE LLC | 2010-06-24 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705028-B2 | Farnesoid X receptor agonists | GLAXOSMITHKLINE LLC (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1962838-A2 | FARNESOID X RECEPTOR AGONISTS | Smithkline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076260-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167356-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885LIFR 2399/4885CYP1A2 163/4885 |
| US-20100160398-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885LIFR 2399/4885CYP1A2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.